Autologous Bone Marrow Mesenchymal Cell Induced Chondrogenesis for the Treatment of Osteoarthritis of Knee.
10.1007/s13770-016-9125-y
- Author:
Sung Woo HUH
1
;
Asode Ananthram SHETTY
;
Jang Mook KIM
;
Mi La CHO
;
Seon Ae KIM
;
Siyoung YANG
;
Young Ju KIM
;
Palaksha Kanive JAVAREGOWDA
;
Nam Yong CHOI
;
Jin KANG
;
Seok Jung KIM
Author Information
1. Department of Orthopaedic Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. peter@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Osteoarthritis;
Total knee arthroplasty;
Chondrogenesis;
Mesenchymal cell induced chondrogenesis;
Economy
- MeSH:
Arthroplasty, Replacement, Knee;
Bone Marrow*;
Chondrogenesis*;
Classification;
Disease Progression;
Follow-Up Studies;
Humans;
Knee;
Osteoarthritis*;
Osteoarthritis, Knee*;
Quality of Life;
Telephone
- From:
Tissue Engineering and Regenerative Medicine
2016;13(2):200-209
- CountryRepublic of Korea
- Language:English
-
Abstract:
Healthy and high quality of life has become the main issue with increasing human life span. Many biological treatments for osteoarthritis of the knee have been tried with limited success. We compared data from 7 patients who underwent total knee arthroplasty and 46 patients who underwent autologous bone-marrow mesenchymal cell induced chondrogenesis (MCIC) for osteoarthritis of grade IV of the Kellgren-Lawrence classification and grade IV of modified Outerbridge classification from 50 to 65 years of age. Clinical evaluation of the 2 groups showed significant improvement in the mean telephone Knee Society Scoring system (tKSS)-A (pain) and tKSS-B (function) scores throughout the postoperative follow-up period. There was no difference in the patients' satisfaction between the 2 groups. MCIC is a treatment option at least for delaying disease progression of osteoarthritis of the knee.
